证券代码：002688 证券简称：金河生物 公告编号：2025-074 金河生物科技股份有限公司 关于公司取得发明专利及外观设计专利证书的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 3、专利权人：金河生物科技股份有限公司 4、地址：010200内蒙古自治区呼和浩特市托克托县新坪路71号 5、发明人：谢昌贤；王福军；侯国峰；谢雪峰；王鹏飞 6、专利号：ZL 2024 1 1662023.9 金河生物科技股份有限公司（以下简称"公司"）于近日获得由国家知识产 权局颁发的发明专利及外观设计专利证书，具体情况如下： （一）发明专利证书 1、证书号：第8146183号 2、发明名称：罐体圆周分布的微生物发酵厂房 6、专利号：ZL 2024 3 0734428.3 7、专利申请日：2024年11月20日 7、专利申请日：2024年11月20日 8、授权公告号：CN 119507713 B 9、授权公告日：2025年08月08日 （二）外观设计专利证书 1、证书号：第9411134号 2、外观设计名称：微生物发酵厂房 3、专利权人：金河生物科技股份有限 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-073 金河生物科技股份有限公司 关于控股股东及一致行动人减持股份触及1%整数倍的公告 公司控股股东内蒙古金河控股有限公司及一致行动人路牡丹、路漫漫、王晓 英、王志军保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 5 月 17 日披露 了《关于控股股东减持股份预披露的公告》，公司控股股东内蒙古金河控股有限 公司（以下简称"金河控股"）计划 2025 年 6 月 10 日至 2025 年 9 月 9 日通过 集中竞价交易、大宗交易方式减持公司股份合计不超过 22,563,389 股，即不超 过公司总股本（总股本按剔除公司回购专用账户中的股份数量 19,521,410 股计 算，下同）的 3%。其中，以集中竞价方式减持公司股份不超过 7,521,130 股（占 总股本比例 1%），以大宗交易方式减持公司股份不超过 15,042,259 股（占总股 本比例 2%）。 公司于 2025 年 ...

Core Insights - The pet economy is evolving from a focus on food and supplies to a comprehensive ecosystem that includes medical care, grooming, training, and insurance [1][3] - The integration of AI technology is driving new momentum in the pet industry, enhancing service capabilities and creating new business models [2][5] Market Overview - In the first half of this year, domestic pet consumption reached 77.375 billion yuan, with a year-on-year growth of 8.84% [1] - The average revenue per pet store in mainland China was approximately 137,500 yuan [1] - The pet consumption market in urban areas is projected to exceed 300 billion yuan by 2024, with the total number of dogs and cats reaching over 120 million [3] - The pet economy is expected to grow to 1.15 trillion yuan by 2028 [3] Industry Trends - The role of pets is shifting from mere companionship to becoming integral family members, leading to increased demand for health management and personalized services [3][4] - AI technologies such as smart image analysis and semantic understanding algorithms are crucial for the intelligent upgrade of pet services [3] - The traditional hardware model is transitioning to a "hardware + service" model, creating a commercial ecosystem through subscription services and accessory sales [3] Company Performance - Listed companies in the pet industry have reported strong performance, with Yantai Zhongchong Food Co., Ltd. achieving a revenue of 2.432 billion yuan, a year-on-year increase of 24.32%, and a net profit of 203 million yuan, up 42.56% [4] - The growth of the pet economy is attributed to evolving consumer attitudes, expanding market demand, and improved industry standards [4] AI Integration - Companies are increasingly incorporating AI into the pet economy, with various enterprises launching AI-driven products and services [5][6] - Jinhe Biotechnology Co., Ltd. plans to launch the "AI Pet Partner" app, which will include features like emotion recognition and AI diagnosis [5] - Anuoqi Group has developed an AI customization service platform for pets, aiming to create a comprehensive ecosystem for pet care [5][6] - Shenzhen Yuanwanggu Information Technology Co., Ltd. is promoting a "hardware + AI + ecosystem" operational model with smart pet devices [6] Future Outlook - The competition in the "AI + pet economy" sector is expected to intensify, focusing on technological depth and data barriers [6] - New business models may emerge, including AI-based pet health management subscription services and AI-driven offline experience stores [6]

Core Insights - The article highlights the launch of "Ai Pet Easy" APP by Jinhe Biological, which is positioned as the world's first AI-driven pet care application that integrates health services and aims to revolutionize the pet economy [1][4]. Company Overview - Jinhe Biological has a strong foundation in animal health, with a comprehensive product line in pet vaccines, pharmaceuticals, and nutritional supplements, which supports the development of the "Ai Pet Easy" APP [1][2]. - The APP features an innovative emotional recognition system powered by the self-developed multimodal model Frank, which can accurately identify pets' emotional states and provide real-time feedback to owners [2][3]. Product Features - "Ai Pet Easy" APP includes multiple core functionalities such as emotional recognition, pet care encyclopedia, points system, interactive community, and personalized shopping [2][3]. - The emotional recognition system has achieved a 92% accuracy rate in identifying typical scenarios like anxiety and gastrointestinal discomfort [2]. - The APP will also offer AI pet consultations, video veterinary services, and legal assistance related to pet ownership, creating a comprehensive service ecosystem [3]. Market Potential - The pet economy is experiencing rapid growth, with the Chinese pet market expected to reach 494.3 billion yuan in 2024 and surpass 800 billion yuan by 2026 [5]. - The global pet economy is projected to exceed 3.2 trillion yuan by 2025, making it a significant area of emotional consumption [5]. - Jinhe Biological aims to leverage AI and big data to transform the pet economy from mere product transactions to a new ecosystem centered on understanding and service [6]. Industry Trends - The pet economy is becoming a new consumption blue ocean, with sectors like pet healthcare, smart hardware, insurance services, and digital content driving growth [5]. - The integration of technology in pet care is expected to unlock new functionalities, such as genetic disease prediction and public safety collaboration [5][6]. - The APP is seen as a platform-level capability that enhances communication between pets and their owners, promoting a more equitable dialogue [6][7].

Core Viewpoint - The article highlights the significant growth and competitive advantages of Jinhe Biological, particularly in the veterinary pharmaceutical sector, driven by rising demand and pricing power in the livestock industry, as well as the burgeoning pet economy in China [1][5]. Group 1: Industry Trends - In the U.S., beef prices have reached historical highs, with ground beef prices increasing by 12% year-on-year in June. In China, the number of beef cattle decreased by 2.33% month-on-month in May, while calf prices surged by 26.37% year-on-year as of July 11 [1]. - The upward trend in calf prices and the decline in beef cattle inventory are expected to support beef prices in the latter half of 2025 and into 2026, indicating a sustained cycle of profitability in the beef industry [3]. Group 2: Company Performance - Jinhe Biological, a leader in the veterinary pharmaceutical market with a 50% global market share in oxytetracycline, has experienced rapid growth in performance this year, with a stock price increase of over 90% by April 10 [1][2]. - The company's net profit attributable to shareholders for the first half of 2025 increased by 51.52% year-on-year, reaching 138 million yuan, driven by increased sales of oxytetracycline and reduced raw material costs [2]. Group 3: Business Strategy and Growth Drivers - The company has established a dual-channel strategy in the pet health sector, with a focus on both imported and domestic brands, and has launched an AI-powered pet care app [4]. - The pet industry in China is projected to grow from 170.8 billion yuan in 2018 to 300.2 billion yuan by 2024, with a compound annual growth rate of 9.86% [4]. - Jinhe Biological's vaccine business is expected to see significant growth, particularly with the brucellosis vaccine, which has a market potential of around 4 billion yuan and could grow to 20 billion yuan due to increased demand and pricing [21]. Group 4: Competitive Advantages - The company benefits from scale advantages that drive cost reductions and efficiency improvements, with plans for a new factory expected to enhance profitability and reduce production costs [12]. - Jinhe Biological has established strong technical barriers and innovation capabilities, collaborating with research institutions to improve product quality and reduce impurities in its products [13][14]. - The company has a diversified business model that includes environmental protection and agricultural product processing, which contribute to stable performance [15]. Group 5: Future Outlook - The company aims to leverage its dual-drivers of pharmaceutical and vaccine segments to transition from a cyclical to a growth-oriented enterprise, indicating long-term investment value [28].

国海证券指出，猪价持续震荡，但下行压力犹在。政策或将保持长期调控方向。生猪行业朝着自律-监 管加剧-纠偏-稳定的方向运行，行业有望从出栏增长逻辑往价值方向回归，头部猪企更为受益。 养殖ETF紧密跟踪中证畜牧养殖指数，中证畜牧养殖指数选取涉及畜禽饲料、畜禽药物以及畜禽养殖等 业务的上市公司证券作为样本，以反映畜牧养殖相关上市公司的整体表现。从估值层面来看，养殖ETF 跟踪的中证畜牧养殖指数最新市盈率（PE-TTM）仅13.4倍，处于近3年12.15%的分位，即估值低于近3 年87.85%以上的时间，处于历史低位。当前板块估值仍在低位、板块安全边际高，建议积极关注养殖 ETF(516760.SH)。 8月6日早盘，养殖ETF(516760)震荡上行，现跌0.15%，成分股金河生物(002688)上涨2.76%，华英农业 (002321)上涨2.69%，海大集团(002311)上涨1.16%，巨星农牧(603477)上涨1.06%，牧原股份(002714)上 涨0.99%。消息面上，中国畜牧业协会发布关于召开猪业分会会长办公会扩大会议的通知。 近日，中央定调"反内卷"已延伸至农产品领域，7月23日农业部会议调控范围 ...

Group 1 - China's assets continue to attract foreign investment due to robust fundamentals, an improving business environment, and high levels of openness [1] - As of August 5, 23 stocks in the top ten shareholders list included Qualified Foreign Institutional Investors (QFII), with a total market value of 3.737 billion yuan, averaging 162 million yuan per stock [2] - Notable QFII holdings include Ninebot Company-WD, Dongfang Yuhong, Haida Group, and Hongfa Technology, each with holdings exceeding 400 million yuan [2] Group 2 - Compared to the end of Q1, five stocks saw an increase in QFII holdings, with 13 stocks receiving new investments, resulting in a 78.26% increase in the number of stocks with increased holdings [3] - WoHua Pharmaceutical experienced the largest increase in QFII holdings, with a 234.76% rise in the number of shares held, driven by new investments from UBS and Barclays [3] - The average increase in stock prices for QFII heavy stocks since April has been 19.59%, with some stocks like DingTong Technology and WoHua Pharmaceutical seeing increases over 60% [4] Group 3 - More than half of the 23 QFII heavy stocks reported positive earnings, with a 54.55% reporting an increase in net profit [4] - Five stocks have announced cash dividend plans, totaling 2.94 billion yuan, with Dongfang Yuhong leading at 2.21 billion yuan [4] - International investment banks are optimistic about the Chinese market, with Morgan Stanley and Deutsche Bank raising their GDP growth forecasts for China [5][6]

证券之星消息，8月5日动物保健板块较上一交易日上涨1.46%，申联生物领涨。当日上证指数报收于 3617.6，上涨0.96%。深证成指报收于11106.96，上涨0.59%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688098 | 申联生物 | 8.83 | 10.79% | 41.07万 | 3.48亿 | | 002141 | 贤丰控股 | 3.81 | 4.10% | 73.27万 | 2.80亿 | | 002688 | 金河生物 | 7.60 | 3.54% | 64.52万 | 4.87亿 | | 300871 | 回盛生物 | 24.82 | 1.85% | 26.04万 | 6.36亿 | | 688526 | 科前生物 | 17.11 | 0.65% | 2.04万 | 3484.70万 | | 600195 | 中牧股份 | 7.67 | 0.52% | 7.69万 | 5893.24万 | | 603718 | 海利生物 | 7.67 ...

证券时报·数据宝统计，截至8月5日，有95家公司公布2025年半年报，其中63家净利润同比增长，32家 同比下降，60家营业收入同比增长，35家同比下降，净利润和营业收入同时增长的公司有智明达等51 家，利润收入均下降的有容百科技等23家，业绩增幅翻倍的公司有15家，其中智明达增幅最大，达 2147.93%。（数据宝） 已公布半年报公司净利润增幅排名 （文章来源：证券时报网） | 代码 | 简称 | 每股收益 | 净利润（万 | 净利润同比 | 营业收入（万 | 营业收入同比 | | --- | --- | --- | --- | --- | --- | --- | | | | （元） | 元） | （%） | 元） | （%） | | 688636 | 智明达 | 0.2284 | 3829.80 | 2147.93 | 29475.64 | 84.83 | | 688313 | 仕佳光 子 | 0.4793 | 21664.75 | 1712.00 | 99262.53 | 121.12 | | 002052 | 同洲电 子 | 0.2722 | 20307.14 | 662.77 | 53976.95 ...

资金面上看，今日动物疫苗概念板块获主力资金净流出0.45亿元，其中，14股获主力资金净流出，净流 出资金居首的是康华生物，今日主力资金净流出3459.86万元，净流出资金居前的还有海正药业、罗牛 山、科兴制药等，主力资金分别净流出1602.33万元、1333.02万元、1153.20万元。今日主力资金净流入 居前的概念股有金河生物、国药现代、生物股份等，主力资金分别净流入5399.57万元、1143.75万元、 931.58万元。（数据宝） 截至8月4日收盘，动物疫苗概念下跌0.39%，位居概念板块跌幅榜前列，板块内，科兴制药、申联生 物、康华生物等跌幅居前，股价上涨的有11只，涨幅居前的有生物股份、金河生物、蔚蓝生物等，分别 上涨2.70%、2.51%、2.10%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 兵装重组概念 | 5.68 | 乳业 | -0.46 | | 军工信息化 | 3.75 | 动物疫苗 | -0.39 | | 军民融合 | 3.53 | 信托概念 | -0.36 | | 成飞概念 ...